$LH

Summy Amy B. sold $283K of LH

Summy Amy B. (EVP, Chief Marketing Officer) sold 924 shares of LABCORP HOLDINGS INC. (LH) at $306.74 ($0.28M total) on 2026-08-04.

Original reporting
SEC EDGAR · Summy Amy B.
Published Aug 6, 2026, 12:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

The disclosure updates insider trading records but does not introduce new company performance, guidance, or regulatory developments.

02

Market read

Traders may note the sale for sentiment, but it is unlikely to change valuation without additional corroborating news.

03

What to watch

The article does not indicate whether the sale was tax-related, diversification-driven, or part of a broader pattern; also no 10b5-1 plan was used per the text.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-06, transaction dated 2026-08-04

Background

SEC Form 4 insider transaction for LABCORP HOLDINGS INC. (LH) by EVP and Chief Marketing Officer Summy Amy B.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

Form 4 shows LH CMO Summy Amy B. sold 924 shares at $306.74 on 2026-08-04, totaling $283,427.76.

Expected impact

Minimal near-term impact; any reaction is likely noise unless paired with other disclosures.

Evidence & confidence

This is a single insider sale, not a buy, not tied to new company guidance, and the filing provides no new operational or financial information.

Market effects

No clear sector read-through from a single marketing executive’s sale.

None.

None.

Counterpoint

Insider sales can sometimes precede negative developments, but this filing lacks any accompanying company-specific catalyst.

Key entities

  • LABCORP HOLDINGS INC.

    Company subject of the Form 4 insider sale disclosure.

  • Summy Amy B.

    EVP, Chief Marketing Officer who sold 924 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LHMed

Why Labcorp Holdings Stock Dropped Today

Labcorp Holdings (LH) stock fell 3.3% after CMS announced plans to cut lab reimbursement rates by up to 15% starting in 2027. CMS payments accounted for 8% of Labcorp's 2025 revenue, according to its SEC filing. The company warned that reduced rates could materially impact its revenue and profitability.

$BABAMed

Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more

Alibaba shares rose 3% after its CEO announced plans for 20+ gigawatts of data centers by 2032 and launched a new chip. Quest Diagnostics and Labcorp fell 5% each due to Medicare payment adjustments. Vicor gained 9% on strong Q3 guidance. On Holding jumped 6% after setting new financial targets and a $1B share buyback plan. GameStop rose 3.5% after its CEO bought 1.2M shares.

$DGXMed

Premarket movers: Quest, Labcorp hit by CMS cuts

U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.

$LHMedAI 8/10

Why is Labcorp stock sliding today?

Labcorp (LH) stock fell 3.4% after-hours to $310 following CMS's proposal to cut Medicare lab reimbursements by up to 15% annually starting 2027. CMS claims this corrects overpayments, potentially saving $1B yearly. Truist raised its price target to $365 but kept a Buy rating. Quest Diagnostics faces similar headwinds. The selloff was sector-specific, with broader markets flat.